Logo

Perlegen and Bristol-Myers Squibb in Pharmacogenomics Deal

Dec 19, 2002

NEW YORK, Dec. 19-Perlegen Sciences will identify pharmacogenomic markers for Bristol-Myers Squibb, the company said today.

 

In the partnership, the companies will use Perlegen's chip-based resequencing technology to scan the genomes of hundreds of participants in clinical trials for markers associated with drug response.

 

Perlegen will apply its collection of more than 1.5 million SNPs to the data in order to identify new markers.

 

Through the deal, Perlegen will get research funding, milestone payments, royalties, and rights to certain diagnostics.

 

Financial details of the partnership were not disclosed.

 

Perlegen is an Affymetrix spinoff based in Mountain View, Calif.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.